SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending after Trump announced a US-Denmark-Greenland agreement granting Washington permanent security access to the island, with traders overwhelmingly bullish that it de-risks the company's Tanbreez heavy rare earth project in Greenland and sets up a potential short squeeze given elevated short interest. Some push back that a security pact doesn't change Tanbreez's economics since offtake commitments already cover planned output, while others view the pact's formal signing and the Trump-Xi summit on critical minerals as additional catalysts.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Retail traders are speculating that Roaring Kitty (Keith Gill) is signaling a return or new buying after his old 'Mr. Wizard' forum account's mood was updated to a row of plus signs, layering squeeze hopes on top of CEO Ryan Cohen's disclosed open-market share purchase. Sentiment on Jim Cramer's bullish 'buy' call is split, with many treating the endorsement as a contrarian 'inverse Cramer' warning.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

Traders are split on the AI trade after Anthropic-led calls to slow frontier AI development rattled semiconductor sentiment, with dip-buyers arguing chip demand and the data-center buildout remain intact while bears point to the slowdown warnings, Michael Burry's disclosed short position in the ETF, and a hawkish Fed backdrop for the volatile swings.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is surging back into double-digit territory on unusually heavy volume, with traders citing the RWA/tokenization narrative  led by NYSE/ICE testing the Avalanche blockchain for 24/7 tokenized securities trading  and a broader altcoin rotation as drivers. Bulls are celebrating a long-awaited recovery after extended underperformance, while skeptics dismiss the move as another pump-and-dump and are locking in profits ahead of an expected reversal.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Traders are fixated on Bitcoin's repeated attempts to break a long-running resistance zone in the low $80,000s, with fresh rejections fueling a bull-versus-bear debate over whether the bear market is over. Bulls point to the weekly close above the 50-week moving averagethe first in monthsas a bottom-confirmation signal, while bears argue the failed breakouts set up a slide back toward the mid-$70,000s.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is drawing heavy attention after a double-digit percentage surge that far outpaced Bitcoin's rebound, which traders attribute to the CLARITY Act's failure in the Senate clearing the path for SEC and CFTC actionincluding regulatory relief for onchain trading of tokenized stocksalongside short covering around a major options expiration. Debate centers on whether the move reflects a durable regulatory tailwind or an unsustainable premium to the company's Bitcoin holdings, with bears warning of dilution from potential new capital raises.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

Traders are focused on REalloys' pending U.S. Army Enhanced Use Lease negotiations at Tooele Army Depot for heavy rare earth processing, which the community expects to conclude by mid-September, alongside its 15-year offtake agreement with Critical Metals Corp's Greenland Tanbreez project  positioning framed around the January 2027 push to remove Chinese rare earths from defense supply chains. Sentiment is split between bulls anticipating the Tooele update and broader critical-minerals momentum, and critics citing months without company news and persistent underperformance versus rare earth peers, with some also speculating about a short squeeze.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Attention is focused on The Trade Desk's removal from the S&P 500 and move to the S&P SmallCap 600, which traders link to exceptionally heavy trading volume as index funds reposition, with debate over whether forced selling was absorbed or further institutional exits loom. Bulls view the index exit as the last near-term negative catalyst and cite elevated short interest as squeeze fuel, while bears point to slowing growth, the 15% workforce reduction, and backlash over CEO Jeff Green's option repricing and executive share grants.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is rallying sharply after the protocol launched confidential-by-default perpetual futures powered by Hyperliquid, a privacy feature traders say is attracting perp flow as part of a broader privacy/AI token run alongside ZEC, with many in the community pointing to a claimed 1:1 correlation with Zcash. Bulls are celebrating the volume spike and framing NEAR as a next-generation L1, while skeptics call the move a whale-driven pump on no fundamental news, and short sellers remain active.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance is trending as shares rally above $10 for the first time in roughly two years, coinciding with an analyst price-target increase from Barclays that cited physician survey support for Amtagvi's durability and momentum ahead of the anticipated NSCLC (lung) data readout. The community is largely bullish, debating short-covering versus options-expiry pinning around the $10 level while awaiting a promised quarterly update to full-year revenue guidance.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EyePoints DURAVYU missed the primary endpoint in the LUGANO Phase 3 wet AMD trial, drawing attention to Ocular Therapeutix as a potentially advantaged competitor with AXPAXLIs FDA-aligned NDA path. Traders are debating whether the setback materially de-risks Oculars program and increases buyout interest, while skeptics argue that competition from established anti-VEGF treatments and uncertainty over TKI adoption remain significant.

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

Equity

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal. 

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.read more...

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.


Notable Wednesday Option Activity: OCUL, LLY, WEN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ocular Therapeutix Inc (Symbol: OCUL), where a total of 25,374 contracts have traded so far, representing approximately 2.5 million underlying shares. That amounts to ab...

OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights

Ocular’s total cash and cash equivalents stood at $598.6 million at the end of the second quarter, which it expects will provide sufficient cash runway until 2028.


Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?

Ocular said its U.S. Food and Drug Administration-aligned New Drug Application for wet age-related macular degeneration therapy is expected to be submitted in the fourth quarter of 2026.

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsOcular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli...

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1

Key PointsAcuta Capital Partners reduced its Ocular Therapeutix holding by 460,887 shares...

What This Fund's $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key PointsSaturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$9.99
Prev Close	$10.14
Open	$10.15
Dividend Yield	0.00%
50-Day Moving Average	$9.87
Beta	1.48
Avg. Volume	2.76M
PE Ratio	-7.07

52-Week High	$16.44
52-Week Low	$6.23
Market Capitalization	$2.19B
EPS (Annual)	-$1.42
Price to Book	4.22
Revenue Per Employee	$159,849.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

OCUL Fundamentals